Medical Letter on the CDC & FDA articles from September 2008

Medical Letter on the CDC & FDA archives from September 2008

PreMD Inc. - FDA Upholds Previous NSE Decision.
September 7, 2008... Predictive medicine company PreMD Inc. (TSX: PMD - News; Amex: PME - News) announced that the U.S. Food and Drug Administration ("FDA") has upheld their decision regarding the company's not substantially equivalent (NSE) letter it received in...

Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV.
September 7, 2008... Rosetta Genomics, Ltd. (NASDQ: ROSG) announced a collaboration with the National Institute of Health to identify microRNAs involved in the progression of the Human Immunodeficiency Virus (HIV), that may be used as potential drug targets (see...

Research conducted at B.L. Metzger and co-researchers has updated our knowledge about hyponatremia.
September 7, 2008... According to recent research published in the journal International Urology and Nephrology, "The treatment of hyponatremia, especially euvolemic and hypervolemic hyponatremia, has changed with the development of drugs which function as...

Research on pharmacology described by scientists at Food & Drug Administration.
September 7, 2008... In this recent study, researchers in the United States conducted a study "To review the labels of United States Food and Drug Administration (FDA)-approved drugs to identify those that contain pharmacogenomic biomarker information, and to...

New cancer research from China Pharmaceutical University discussed.(Report)
September 7, 2008... Research findings, 'Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells,' are discussed in a new report. According to recent research published in the...

Research on plague reported by scientists at University of California.
September 7, 2008... "Yersinia pestis, the agent of bubonic plague, evolved from the enteric pathogen Yersinia pseudo tuberculosis within the past 20,000 years. Because ancestor and descendant both exist, it is possible to infer steps in molecular evolution by...

Investigators at National Institutes of Health target west nile virus.
September 7, 2008... According to a study from the United States, "West Nile virions incorporate 180 envelope (E) proteins that orchestrate the process of virus entry and are the primary target of neutralizing antibodies. The E proteins of newly synthesized West...

New findings in west nile virus prevention described from National University of Singapore, Department of Microbiology.(Report)
September 7, 2008... A report, 'Inhibition of West Nile virus replication in cells stably transfected with vector-based shRNA expression system,' is newly published data in Virus Research. "In this study, the efficacies of short hairpin RNAs (shRNAs) targeting...

Studies conducted at M. Joner et al on life sciences recently published.(Report)
September 14, 2008... According to recent research published in the Journal of the American College of Cardiology, "Objectives The purpose of this study was to assess trends in endothelial coverage and recovery among leading polymer-based drug-eluting stents ( DES)....

NexMed Announces Decision for NM100060.(Clinical report)
September 14, 2008... NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT(R) drug delivery technology, announced that based on First Interpretable Results of Phase III clinical studies for NM100060, a topical application of terbinafine...

Valeant Pharmaceuticals and GlaxoSmithKline Announce Worldwide Collaboration Agreement for Retigabine.
September 14, 2008... Valeant Pharmaceuticals International (NYSE:VRX) and GlaxoSmithKline (GSK) announced that they have entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine, a first in class neuronal potassium channel...

Trends in Prescription Medication Sharing Among Reproductive-Aged Women Reported in Journal of Women's Health.
September 14, 2008... Borrowing and sharing of prescription medications is a serious medical and public health concern. A survey of nearly 7,500 women of reproductive age found that this is common practice among more than one-third of this population, according to a...

Investigators at Veterans Affairs Medical Center zero in on HIV/AIDS therapy.
September 14, 2008... A report, 'Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection,' is newly published data in Clinical Therapeutics. "The emergence of viral resistance is one of the greatest challenges in the treatment of HIV infection....

DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties.
September 14, 2008... After encouraging results following the first night of aerial treatments, the Department of Environmental Protection will continue its efforts this evening to protect the public against the mosquito-borne West Nile virus (see also West Nile...

Phase III U.S. Pivotal Study Results On CSL Biotherapies Afluria[R] Published In Vaccine.
September 21, 2008... Phase III pivotal study findings published in the journal Vaccine showed that two formulations of CSL Biotherapies' influenza virus vaccine Afluria[R] elicited an immune response (also known as immunogenicity) in healthy adults aged 18- ...

Findings from Baylor College of Medicine, College of Medicine advance knowledge in influenza.
September 21, 2008... According to a study from the United States, "Influenza viruses cause annual winter epidemics in temperate regions, with significant morbidity, mortality and economical impact. Fluarix(R) is a split, trivalent, inactivated vaccine, manufactured...

Natural Products Association, Virgo Publishing to Conduct In-depth GMP Training Before SupplySide West.
September 21, 2008... When the FDA's GMP rule becomes effective for your dietary supplement company, will your business be ready? It isn't a question to gamble on -- noncompliance can damage your operations and cripple your business. By June 25, 2010, all supplement...

Recent findings from Carnegie Mellon University highlight research in behavior.
September 21, 2008... Scientists discuss in 'The impact of over-the-counter availability of "Plan B" on teens' contraceptive decision making' new findings in behavior. "In ruling on the over-the-counter status (OTC) of the emergency contraceptive, 'Plan B', the US...

Study data from B. Horowitz and colleagues update understanding of fibrin tissue adhesives.(Report)
September 21, 2008... New research, 'Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin,' is the subject of a report. "Plasma fractionators have implemented many improvements over the past decade...

Reports outline Escherichia coli research from Department of Agriculture.
September 21, 2008... According to recent research from the United States, "Chlorate salts are being developed as a feed additive to reduce the numbers of pathogens in feedlot cattle. A series of studies was conducted to determine whether chlorate, at concentrations...

Ultimate Labs Takes Quality Testing to a New Level with Unique Ulti-Pak Service and ISO 9001 Certification.
September 21, 2008... Ultimate Labs, (www.ultimatelab.com) a newly ISO 9001 certified microbiological testing and environmental monitoring firm located in the heart of San Diego's biotech community, introduces the Ulti-Pak, a new system to store and transport lab...

New HIV/AIDS study findings reported from E. Seminari and co-authors.
September 28, 2008... "Etravirine (TMC 125) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that is being developed for the treatment of HIV-1 infections. The drug was recently approved by the US FDA to be used in combination with other...

Research from Stanford University provides new data about life sciences.
September 28, 2008... "It is known that many potent, often aromatic drugs are water insoluble, which has hampered their use for disease treatment. In this work, we functionalized nanographene oxide (NGO), a novel graphitic material, with branched polyethylene glycol...

New regulatory actions study findings reported from C.A. Stockl and co-authors.
September 28, 2008... "The utilization of controller medications before initiating a long-acting beta(2)-adrenergic agonist (LABA) before and after the Food and Drug Administration (FDA) alerts is examined. Electronic claims from a health insurer in the Western...

Department of Health Confirms Additional West Nile Cases in Southeastern PA.
September 28, 2008... The Pennsylvania Department of Health announced three newly confirmed cases, and one suspected case, of West Nile virus infection in southeastern Pennsylvania. This brings the number of cases reported in Pennsylvania this season to five (see...

PharmacoEconomics Publishes Special 'Fourth Hurdle' Issue Related to U.K.'s National Institute for Health and Clinical Excellence (NICE).
September 28, 2008... Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry, published a special issue of Adis...

Studies from University of Michigan yield new information about legionnaire disease.
September 28, 2008... "Experiments were performed to determine the contribution of TLR9 to the generation of protective immunity against the intracellular respiratory bacterial pathogen Legionella pneumophila. In initial studies, we found that the intratracheal...

New findings from G. Caroline and co-researchers in the area of plague described.(Report)
September 28, 2008... A new study, 'Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis,' is now available. "Protective antigens of Pseudomonas aeruginosa (PcrV) and Yersinia pestis (LcrV) are key elements of...

Oculus Innovative Sciences Reduces Planned Expenses While Accelerating Global Commercialization.
September 28, 2008... Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced that it is significantly reducing planned expenses, including the shift of a planned $30 million pivotal trial cost to a potential partner, while the company prepares for the launch of...